Life Sciences Tools and Services
Company Overview of mBio Diagnostics, Inc.
mBio Diagnostics, Inc. develops clinical diagnostics and sample testing products that deliver on-the-spot results. It offers MBio multiplex analyzers and disposable cartridges that are used for clinical and analytical testing applications in medical, veterinary, environmental, food, agricultural, and military markets. It also provides MBio array systems, which are multiplexed fluorescence immunoassay systems that provide the simultaneous measurement of multiple analytes from a single sample; and LightDeck devices, which are fluorescence assay illumination systems. The company was founded in 2009 and is based in Boulder, Colorado.
5603 Arapahoe Avenueo
Boulder, CO 80301
Founded in 2009
Key Executives for mBio Diagnostics, Inc.
Founder, Chief Executive Officer and Director
Director of Finance & Administration
Chief Technology Officer and Executive Vice President
Compensation as of Fiscal Year 2016.
mBio Diagnostics, Inc. Key Developments
MBio Diagnostics, Inc. Announces Development Collaboration with Cincinnati Children's Hospital Medical Center
Sep 13 16
MBio Diagnostics, Inc. announced a product development collaboration with Cincinnati Children's Hospital Medical Center. Researchers at Cincinnati Children's, led by Hector Wong, MD, director, Division of Critical Care Medicine, have been investigating biomarker panels that provide prognostic and predictive patient stratification, particularly in the context of septic shock. MBio will collaborate with Dr. Wong to develop a multi-marker panel to risk stratify patients with septic shock in a clinically relevant time frame. Prognostic and predictive patient stratification are fundamental elements of precision medicine, which seeks to target patient populations in which a drug or intervention is more likely to be effective. Prognostic enrichment strategies select patients with a greater likelihood of having a disease-related event. Predictive enrichment strategies select patients who are more likely to respond to an intervention or drug, based on a biological or physiologic mechanism. Enrichment strategies are particularly effective when selecting patients for treatment trials in highly heterogeneous syndromes, such as septic shock. By using prognostic and predictive strategies in trial design, therapies for critically ill patients can be optimized more quickly. Ultimately this approach will provide precision guidance to therapy in the clinic. In the context of critical care, these precision medicine techniques would ideally be carried out in real-time. The MBio Array System utilizes MBio's proprietary LightDeck technology, which enables simple, multiplex testing in a compact system. This portable, easy-to-use multiplex reader can be placed into a wide variety of clinical situations, including directly placed in the intensive care unit (ICU).
mBio Diagnostics, Inc. Presents at Redefining Early Stage Investments (RESI) Conference, Sep-13-2016
Sep 9 16
mBio Diagnostics, Inc. Presents at Redefining Early Stage Investments (RESI) Conference, Sep-13-2016 . Venue: The Westin Copley Place, 10 Huntington Ave, Boston, MA 02116, United States.
mBio Diagnostics, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016
Jan 7 16
mBio Diagnostics, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016 . Venue: Marine's Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 17, 2016